Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025 [9] - Full-year 2025 total revenue was $605.5 million, representing approximately 37% growth year-over-year [10] - Operating profit for Q4 was approximately $21.3 million, representing approximately 13.2% of total revenue for the quarter [9] - Full-year operating profit was approximately $108.6 million, representing approximately 18% of total revenue [10] - Net income for Q4 was $105 million, significantly increasing year-over-year and sequentially, including an income tax benefit of $83.8 million [30][31] - Earnings per share for Q4 were $3.08, and diluted earnings per share were $2.62 [31] Business Line Data and Key Metrics Changes - U.S. transplant revenue grew approximately 11% sequentially to $155 million in Q4 2025, while OUS transplant revenue grew approximately 33% sequentially to $5 million [9] - Transplant logistics service revenue for Q4 was approximately $28.6 million, up from $21.7 million in Q4 2024, representing approximately 32% year-over-year growth [10] - Product revenue for Q4 was $100 million, up 34% year-over-year, while service revenue was $60 million, up 29% year-over-year [27] Market Data and Key Metrics Changes - Total U.S. OCS transplants performed in 2025 were 5,139, up from 3,735 in 2024, representing approximately 26% of the total 19,833 U.S. transplants for the year [12][13] - U.S. liver transplant volume represented 4,197 transplants, or 36% of the overall liver transplant volume in the U.S., up from 26% in 2024 [14] - U.S. heart transplant volume represented 854 cases, approximately 18% of the overall heart transplant volume, up from 17% in 2024 [15] Company Strategy and Development Direction - The company aims to expand the utilization of available donor organs for transplantation and improve clinical outcomes for transplant patients worldwide [8] - Key growth catalysts for 2026 include the OCS and Enhanced Heart Program, OCS De Novo lung program, and expansion into European markets [20][23] - The company is focused on building a logistics infrastructure in Europe and expanding its clinical support infrastructure [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming future challenges and emphasized the importance of innovation in disrupting inefficient transplant processes [8] - The company anticipates revenue growth of 20%-25% for full-year 2026, translating to a revenue range of approximately $727-757 million [25][35] - Management acknowledged potential operational challenges, including the build-out of logistics infrastructure in Europe and the timing of clinical trial accruals [24] Other Important Information - The company ended the year with approximately $488.4 million in cash and cash equivalents, reflecting strong operating cash generation [10][31] - Total operating expenses for Q4 were $72 million, up 14% year-over-year, driven by increased R&D investment and strategic growth initiatives [28] Q&A Session Summary Question: Guidance for 2026 - Management emphasized that guidance reflects a realistic outlook considering both opportunities and challenges, allowing for execution to dictate future adjustments [44][46] Question: OCS Liver Registry Publication - Management confirmed that health economic data on liver transplants is already published, with upcoming publications expected to demonstrate statistical superiority in outcomes [49][50] Question: NOP Connect 2.0 Operational Efficiencies - Management reported early positive results from NOP Connect 2.0, indicating improved efficiency in management and billing processes [53][54] Question: Competitive Dynamics in Clinical Trials - Management acknowledged competitive dynamics affecting the ENHANCE trial but expressed confidence in executing the trial with robust protocols [60][61] Question: OPO Changes and Broader Environment - Management supported proposed changes in the organ transplant system, aiming for increased competition and efficiency [67] Question: Operating Margin Guidance for 2026 - Management indicated that a significant portion of the incremental investment in 2026 is transitory, with expectations for margin normalization post-investment [70][71]

Summary of TransMedics Group FY Conference Call (December 02, 2025) Company Overview - **Company**: TransMedics Group (NasdaqGM:TMDX) - **Industry**: Medical Technology, specifically organ transplantation Key Points and Arguments Machine Perfusion Adoption - Current adoption of machine perfusion for liver transplants is approximately **40%** [14] - The company aims to increase this adoption to **80-90%** through aggressive efforts and data publication [14] - Significant survival differences and improvements in post-transplant complication rates are associated with the use of OCS machine perfusion [14] Data and Growth Potential - Major publications from liver registry data are expected in the **first half of 2026** [17] - DCD (Donation after Circulatory Death) liver adoption is around **60%**, while DBD (Donation after Brain Death) is only in the mid-20s, indicating room for growth [18] - Approximately **70%** of DCD livers are currently discarded, presenting a significant opportunity for market expansion [18] Transplant Goals - The company is confident in achieving a target of **10,000 transplants by 2028**, regardless of additional growth opportunities [23] - The growth strategy includes increasing utilization in existing centers and onboarding new centers [26] Competitive Landscape - The company welcomes competition, viewing it as a means to maintain market integrity [131] - TransMedics has a strong balance sheet with nearly **$500 million**, which will be invested back into the business [131] Clinical Trials and New Technologies - Enrollment for heart clinical trials has begun, with expectations for lung trials to start by early January [38] - The company is optimistic about replicating the success seen in liver transplants for heart and lung transplants [42] - A new **Gen3 OCS** system is in development, aimed at significantly improving efficiency and reliability for future transplant volumes [126] Kidney Transplant Market - The company plans to enter the kidney transplant market in **2027**, which has a potential volume of **23,000** transplants annually [100] - Current kidney utilization rates are low at **60-65%**, and complications post-transplant are high, indicating a need for improvement [105][106] Financial Outlook - The company aims to achieve an operating margin of **30% by 2028**, driven by growth, disciplined operating expenses, and margin protection [69][136] - There may be a slight impact on gross margins due to costs associated with clinical trials [66] Operational Efficiency - The company is working on increasing the efficiency of its transportation logistics, including double-shifting pilots to maximize jet utilization [73][80] - The goal is to run jets more efficiently, potentially reducing the need for additional aircraft purchases [78] Conclusion - TransMedics Group is positioned for significant growth in the organ transplant market, with a focus on increasing adoption of machine perfusion technology, expanding into new organ markets, and maintaining a strong financial outlook. The company is actively working on clinical trials and new technologies to enhance transplant outcomes and operational efficiency.